CD276 and neoplasm: In addition, B7-H3 is expressed in both RCC cells and tumor vessels and was marked as expressed in RCC vasculatures in some studies as high as 98% [15], which indicates that B7-H3 could act as a potent new cancer vessel-specific carrier to selectively deliver antiangiogenic or vascular-disrupting agents to diseased tissues, minimize any potential side effects, and could help predict the clinical outcome of using different targeted agents in the treatment of RCC.